Pegfilgrastim overdose: case report and review of the literature

Kaidar‐Person, Orit; Moskovitz, Mor; Charas, Tomer; Alsharbati, Wasim; Haim, Nissim

doi:10.1007/s12032-010-9751-5

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pegfilgrastim is a relatively well-tolerated drug, but bone pain is the most common side effect associated with it (8,9). Nonsteroidal anti-inflammatory drugs (NSAIDS), antihistamines, and opioids are used to treat this complication (10)(11)(12). Some of the complications of NSAIDs are the increased risk of acute renal failure and gastrointestinal complications, which are more common in people with a history of gastrointestinal complications, age older than 60 years, high doses of NSAIDs, and concomitant use of corticosteroids and anti-coagulants.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of “Naproxen and Loratadine” Versus “Acetaminophen and Loratadine” on Relief of Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF)-Induced Bone Pain During Chemotherapy; A Randomized Controlled Trial

et al. 2020

View full text Add to dashboard Cite

Background: Pegylated granulocyte colony stimulating factor (PEG-G-CSF) is used as prophylaxis to reduce the risk of neutropenic fever, as a complication of chemotherapy. Bone pain is one of this drug complications. Although we do not have a standard treatment for controlling the secondary pain due to PEG-G-CSF, the combination of Naproxen and Loratadine has shown good results in several studies. Objectives: The purpose of this study was to compare the non-inferiority of Acetaminophen-Loratadine combination due to its lower complications with the known Naproxen-Loratadine combination in patients with cancer. Methods: Total of 200 patients with solid tumor and lymphoma were randomly assigned to the groups of A (Naproxen and Loratadine), and B (Acetaminophen and Loratadine), and the treatment were applied. During the chemotherapy weeks, after each chemotherapy session, pain scores were evaluated on a pain questionnaire according to the designed schedule. Finally both groups were compared. Results: The median age of patients in the Acetaminophen group was significantly higher than the Naproxen group (P < 0.001). The mean pain score of patients before chemotherapy was 1.07 in the Naproxen group and 1.67 in the Acetaminophen group. There was a statistically significant difference in patients' average pain between the two groups before the start of chemotherapy (P < 0.001). After controlling the effect of age, sex, and baseline pain, it was observed that the mean pain score in all courses in the Acetaminophen group was higher than the Naproxen group (P = 0.044). Conclusions: By controlling the effects of age, sex, and baseline pain, Naproxen in the second and subsequent courses of treatment was significantly better than Acetaminophen in reducing pain.

show abstract